107 related articles for article (PubMed ID: 15553926)
1. HIV-1 reverse transcriptase variants: molecular modeling of Y181C, V106A, L100I, and K103N mutations with nonnucleoside inhibitors using Monte Carlo simulations in combination with a linear response method.
Smith MB; Ruby S; Horouzhenko S; Buckingham B; Richardson J; Puleri I; Potts E; Jorgensen WL; Arnold E; Zhang W; Hughes SH; Michejda CJ; Smith RH
Drug Des Discov; 2003; 18(4):151-63. PubMed ID: 15553926
[TBL] [Abstract][Full Text] [Related]
2. Molecular modeling calculations of HIV-1 reverse transcriptase nonnucleoside inhibitors: correlation of binding energy with biological activity for novel 2-aryl-substituted benzimidazole analogues.
Kroeger Smith MB; Hose BM; Hawkins A; Lipchock J; Farnsworth DW; Rizzo RC; Tirado-Rives J; Arnold E; Zhang W; Hughes SH; Jorgensen WL; Michejda CJ; Smith RH
J Med Chem; 2003 May; 46(10):1940-7. PubMed ID: 12723956
[TBL] [Abstract][Full Text] [Related]
3. Monte Carlo calculations on HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor 8-Cl TIBO: contribution of the L100I and Y181C variants to protein stability and biological activity.
Smith MB; Lamb ML; Tirado-Rives J; Jorgensen WL; Michejda CJ; Ruby SK; Smith RH
Protein Eng; 2000 Jun; 13(6):413-21. PubMed ID: 10877852
[TBL] [Abstract][Full Text] [Related]
4. Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations.
Rizzo RC; Udier-Blagović M; Wang DP; Watkins EK; Kroeger Smith MB; Smith RH; Tirado-Rives J; Jorgensen WL
J Med Chem; 2002 Jul; 45(14):2970-87. PubMed ID: 12086483
[TBL] [Abstract][Full Text] [Related]
5. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
Benjahad A; Croisy M; Monneret C; Bisagni E; Mabire D; Coupa S; Poncelet A; Csoka I; Guillemont J; Meyer C; Andries K; Pauwels R; de Béthune MP; Himmel DM; Das K; Arnold E; Nguyen CH; Grierson DS
J Med Chem; 2005 Mar; 48(6):1948-64. PubMed ID: 15771439
[TBL] [Abstract][Full Text] [Related]
6. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
[TBL] [Abstract][Full Text] [Related]
7. Structural and energetic analyses of the effects of the K103N mutation of HIV-1 reverse transcriptase on efavirenz analogues.
Udier-Blagović M; Tirado-Rives J; Jorgensen WL
J Med Chem; 2004 Apr; 47(9):2389-92. PubMed ID: 15084137
[TBL] [Abstract][Full Text] [Related]
8. Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125.
Udier-Blagović M; Tirado-Rives J; Jorgensen WL
J Am Chem Soc; 2003 May; 125(20):6016-7. PubMed ID: 12785806
[TBL] [Abstract][Full Text] [Related]
9. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations.
Das K; Bauman JD; Clark AD; Frenkel YV; Lewi PJ; Shatkin AJ; Hughes SH; Arnold E
Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1466-71. PubMed ID: 18230722
[TBL] [Abstract][Full Text] [Related]
10. Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method.
Smith RH; Jorgensen WL; Tirado-Rives J; Lamb ML; Janssen PA; Michejda CJ; Kroeger Smith MB
J Med Chem; 1998 Dec; 41(26):5272-86. PubMed ID: 9857095
[TBL] [Abstract][Full Text] [Related]
11. Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations.
Rizzo RC; Tirado-Rives J; Jorgensen WL
J Med Chem; 2001 Jan; 44(2):145-54. PubMed ID: 11170624
[TBL] [Abstract][Full Text] [Related]
12. Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants.
Frey KM; Puleo DE; Spasov KA; Bollini M; Jorgensen WL; Anderson KS
J Med Chem; 2015 Mar; 58(6):2737-45. PubMed ID: 25700160
[TBL] [Abstract][Full Text] [Related]
13. Cross-resistance analysis and molecular modeling of nonnucleoside reverse transcriptase inhibitors targeting drug-resistance mutations in the reverse transcriptase of human immunodeficiency virus.
Yang SS; Pattabiraman N; Gussio R; Pallansch L; Buckheit RW; Bader JP
Leukemia; 1997 Apr; 11 Suppl 3():89-92. PubMed ID: 9209308
[TBL] [Abstract][Full Text] [Related]
14. Effects of drug resistance mutations L100I and V106A on the binding of pyrrolobenzoxazepinone nonnucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex.
Locatelli GA; Campiani G; Cancio R; Morelli E; Ramunno A; Gemma S; Hübscher U; Spadari S; Maga G
Antimicrob Agents Chemother; 2004 May; 48(5):1570-80. PubMed ID: 15105107
[TBL] [Abstract][Full Text] [Related]
15. A study of the binding energies of efavirenz to wild-type and K103N/Y181C HIV-1 reverse transcriptase based on the ONIOM method.
Srivab P; Hannongbua S
ChemMedChem; 2008 May; 3(5):803-11. PubMed ID: 18338369
[TBL] [Abstract][Full Text] [Related]
16. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK
Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877
[TBL] [Abstract][Full Text] [Related]
17. Structure-directed linker optimization of novel HEPTs as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Hao QQ; Chen XM; Pannecouque C; De Clercq E; Wang S; Chen FE
Bioorg Chem; 2023 Apr; 133():106413. PubMed ID: 36791619
[TBL] [Abstract][Full Text] [Related]
18. Structural optimization of N
Monforte AM; De Luca L; Buemi MR; Agharbaoui FE; Pannecouque C; Ferro S
Bioorg Med Chem; 2018 Feb; 26(3):661-674. PubMed ID: 29291935
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.
Li X; Gao P; Huang B; Zhou Z; Yu Z; Yuan Z; Liu H; Pannecouque C; Daelemans D; De Clercq E; Zhan P; Liu X
Eur J Med Chem; 2017 Jan; 126():190-201. PubMed ID: 27750153
[TBL] [Abstract][Full Text] [Related]
20. Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations.
Rodríguez-Barrios F; Gago F
J Am Chem Soc; 2004 Dec; 126(47):15386-7. PubMed ID: 15563158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
